Clinical Trials Browser

Phase 2 × cemiplimab × Breast × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06860815 2026-01-28

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Phase 2 Recruiting

11 enrolled

Breast

Breast Neoplasms

NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase 2 Terminated

77 enrolled 18 charts

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

36 enrolled

Breast

Invasive Breast Cancer

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Clinical Trials

I-SPY

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

CemiHALT

Immunological Variables Associated to ICI Toxicity in Cancer Patients